Advanced Search
Your search returned 34 results
  • Oct 7, 2014
    FDA-Approved System Provides Patients with Added Benefits While Testing Innovative Therapy for Bladder and Bowel Incontinence

    MINNEAPOLIS - October 7, 2014 - After living with overactive bladder and urinary retention symptoms for 11 years, Jennifer LaForest, a 26-year-old woman from Auburn Hills, Michigan, recently...

  • Jul 21, 2011
    Distance Runners from Around the World Who Benefit from Medical Technology to Run Medtronic Twin Cities Marathon Events this Fall

    MINNEAPOLIS, Jul 21, 2011 (BUSINESS WIRE) -- Twenty-five long-distance runners who benefit from medical technology will be honored as "Medtronic Global Heroes" when they run the Medtronic Twin...

  • May 24, 2011
    Record Fourth Quarter Revenue of $4.3 Billion Driven by Strong International Growth of 12%

    MINNEAPOLIS, May 24, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE:MDT) today announced financial results for its fourth quarter and fiscal year ended April 29, 2011. Medtronic recorded fiscal...

  • Apr 1, 2011
    Unique Sacral Nerve Stimulation Therapy Now Available for Treatment of Chronic Fecal Incontinence

    MINNEAPOLIS, Apr 01, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval of InterStim(R) Therapy for Bowel Control. InterStim...

  • Mar 3, 2011
    Consensus Paper Suggests Medtronic ITB Therapy is an Effective Treatment for Control of Severe Spasticity, a Frequent and Disabling Symptom of MS

    MINNEAPOLIS, Feb 03, 2011 (BUSINESS WIRE) -- A new scientific article has been published demonstrating the profound impact of spasticity on patients with multiple sclerosis and the benefits and...

Show 5102550100 per page